Neurotech is anticipating results from its extended world first study of a medicinal cannabis product in children which could be a game-changer in autism treatment. Read the full story here.
Stockhead
Neurotech International appoints industry expert during key phase of growth
Neurotech International has made key appointments and changes to its board as it focuses on its developing and commercialising neurological solutions, including a cannabis breakthrough for paediatric autism.
Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism
Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
Neurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
Neurotech tackles the anguish of autism with low-THC cannabis treatment
A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed Neurotech International aims to change.
Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
The company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.
ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac
Neurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.
Neurotech just started world’s first THC-less cannabis study in autistic children
The Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.